AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB

Background Patients with axial spondyloarthritis (axSpA) can experience a significant burden due to the pain, fatigue and impaired physical function resulting from the disease.[1] Objectives To assess how achievement of increasingly stringent clinical response criteria and lower disease activity levels translates into improvements in physical function, sleep and health-related quality of life (HRQoL) in patients with axSpA. Methods This post hoc analysis reports results from the phase 3 studies, BE MOBILE 1 (NCT03928704; non-radiographic axSpA [nr-axSpA]) and BE MOBILE 2 (NCT03928743; radiographic axSpA [r-axSpA], i.e., ankylosing spondylitis[2]) at Week (Wk) 52. In BE MOBILE 1, patients met the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA and had elevated C-reactive protein and/or MRI sacroiliitis. In BE MOBILE 2, patients had radiographic sacroiliitis, fulfilling modified New York criteria. All patients who completed Wk 52 and reached specified clinical response criteria (ASAS: ASAS20 not reached [